Get the Stockscreener App
187.46
0.83%
1.46
Biogen Inc stock is traded at $187.46, with a volume of 769.42K.
It is up +0.83% in the last 24 hours and up +6.66% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$186.00
Open:
$186.74
24h Volume:
769.42K
Relative Volume:
0.40
Market Cap:
$27.50B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
17.93
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+5.47%
1M Performance:
+6.66%
6M Performance:
+40.99%
1Y Performance:
+24.41%
1-Day Range:
$186.49
$190.20
1-Week Range:
$171.61
$190.20
52-Week Range:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
187.47 | 27.29B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,073.16 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.80 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.69 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.73 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.84 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy - TipRanks
Bernstein Adjusts Price Target on Biogen to $197 From $157, Maintains Market Perform Rating - MarketScreener
Biogen’s Alzheimer’s Treatment Gains Crucial Momentum in Chinese Market - AD HOC NEWS
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st
Responsive Playbooks and the BIIB Inflection - Stock Traders Daily
How Biogen Inc. stock performs in high volatility marketsJobs Report & Weekly Watchlist of Top Performers - ulpravda.ru
Will Biogen Inc. stock continue dividend increasesJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
How Biogen Inc. stock compares to growth peersEarnings Growth Summary & Verified Entry Point Detection - ulpravda.ru
Will Biogen Inc. stock split again soonJuly 2025 EndofMonth & Fast Momentum Stock Entry Tips - ulpravda.ru
What catalysts could drive Biogen Inc. stock higherJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - ulpravda.ru
Truist Securities Raises Price Target for Biogen (BIIB) Amid Hol - GuruFocus
RBC Raises Price Target on Biogen to $220 From $210, Keeps Outperform Rating - MarketScreener
Mizuho raises Biogen stock price target to $207 on improved 2026 catalyst outlook - Investing.com Canada
Biogen : to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - MarketScreener
Biogen to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - Biogen
Citigroup Raises Price Target for Biogen (BIIB) to $180, Keeps N - GuruFocus
UBS Adjusts Price Target on Biogen to $185 From $130, Maintains Neutral Rating - MarketScreener
Biogen stock hits 52-week high at 185.59 USD By Investing.com - Investing.com South Africa
Biogen stock hits 52-week high at 185.59 USD - Investing.com
UBS Adjusts Price Target for Biogen (BIIB) with Neutral Rating | - GuruFocus
Analyst Expectations For Biogen's Future - Benzinga
What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Yahoo Finance
Spinal Muscular Atrophy Market Insights 2026-2033: Global - openPR.com
Biogen stock rating maintained at Neutral by UBS, price target raised - Investing.com Canada
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate a Ruthless Market? - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Biogen
Biogen Stock at a Crossroads: Alzheimer Hopes, Biotech Volatility and a Market Running Out of Patien - AD HOC NEWS
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment - Benzinga
Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative? - simplywall.st
Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Yahoo Finance
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer's Disease - MarketScreener
Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail
Will Biogen Inc. stock benefit from sector rotationSwing Trading Ideas & Small Investment Trading Plans - bollywoodhelpline.com
Biogen’s Stock Awaits Key Regulatory Catalyst in China - AD HOC NEWS
BIIB: Biogen's LEQEMBI Application Accepted in China - GuruFocus
Eisai and Biogen Announce Acceptance of Biologics License Application for Subcutaneous LEQEMBI® in China - Quiver Quantitative
Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - MarketScreener
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - Biogen
Biologics License Application for Subcutaneous Formulation - GlobeNewswire
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe - BioSpace
Inside Biotech: A potential paradigm shift in Alzheimer’s therapy — reversal, not just slowing - Proactive financial news
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biosimilars Market is expected to reach US$ 171.79 billion - openPR.com
Biogen Inc. $BIIB Stock Position Increased by Cwm LLC - MarketBeat
Biotech pioneer who helped launch Biogen dies at 94 - The Business Journals
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha
Dementia Drugs Market 2025 Outlook: In-Depth Insights, - openPR.com
Ethic Inc. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Spinal Muscular Atrophy Market is expected to reach US$ 20.06 - openPR.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):